MedTrace Logo

Identifying Therapeutic Hemodialysis Targets Through Cerebrovascular Reactivity; RESPIRACT 2

NCT05445219 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2026-05-04

No results posted yet for this study

Summary

Patients with chronic kidney disease receiving hemodialysis (HD) suffer from higher rates of brain vascular disease and decreased cognition than the general population. One way to assess brain vascular health and response to HD stress, is to test how the brain's blood flow responds to carbon dioxide (CO2) to measure Cerebrovascular Reactivity (CVR). In this study, the investigators will compare the magnitude and speed of the brain's blood flow response to a step-wise change in CO2 with hemodynamic, dialysis, and cognitive parameters. The goal of the study is to establish therapeutic targets that can be altered during the dialysis procedure to protect the brain from HD stress.

Conditions

  • Chronic Kidney Failure

Interventions

DIAGNOSTIC_TEST

RespirAct

The RespirAct device is an automated breathing circuit that uses a gas bladder to control and deliver CO2 to measure cerebrovascular reactivity

Sponsors & Collaborators

  • Heart and Stroke Foundation of Canada

    collaborator OTHER

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Christopher W McIntyre, MD/PHD · London Health Sciences Centre - Victoria Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-20
Primary Completion
2024-10-31
Completion
2026-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05445219 on ClinicalTrials.gov